Acute Exercise and Endogenous Glucose Production in Type 2 Diabetes: Implications for Glycemic Control and Treatment of Hepatic Steatosis

Recruiting now · Not applicable

Conditions studied: Type 2 Diabetes, Hepatic Steatosis

In brief

The overall aim of this study is to investigate the effects of exercise on the amount of glucose that is made by the liver in people with and without Type 2 diabetes (T2D) and hepatic steatosis (fatty liver).

Key facts

Study ID

NCT06993454

Run by

AdventHealth Translational Research Institute

People needed

12

Starts

2025-04-25

Expected to finish

2026-04-01

Last updated by the study team

2026-04-17

Who can join

Age: 25 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may not qualify if…

• Exclusion criteria for individuals with T2D and elevated liver fat ≥5.6% Currently taking insulin, incretin mimetics, and/or thiazolidinediones
• Any change in glucose-lowering medications within the previous three months.
• Inability to stop any medications which interfere with glucose metabolism for visits 4 and 7.
• Resting blood pressure ≥ 160/100 mm Hg
• Triglycerides ≥ 500 mg/dL
• Any renal, cardiac, liver, lung, or neurological disease that in the opinion of the principal investigator would compromise participant safety or the participants' ability to complete the exercise protocol
• Any significant disease or unstable medical condition (i.e., coronary heart disease, chronic renal failure, chronic hepatic disease, severe pulmonary disease)
• Presence of clinically significant abnormalities on electrocardiogram (ECG) that is a contra-indication to exercise testing
• Cancer (active malignancy with or without concurrent chemotherapy; except for basal cell carcinoma)
• Pregnancy during the previous 6 months, lactating, or planned pregnancy in the next 6 months
• Post- or peri-menopausal women
• Partial and/or full hysterectomy (self-report)
• Use of drugs known to affect energy metabolism or body weight: including, but not limited to orlistat, sibutramine, ephedrine, phenylpropanolamine, corticosterone, etc
• Hyperthyroidism including those with normal TSH (0.35-4.5) on pharmacological treatment; individuals with hypothyroidism may be referred to their primary care provider for evaluation and retested; any medication change for hypothyroidism must be stable for ≥3 months prior to retesting
• Current treatment with blood thinners or anti-platelet medications that cannot be safely stopped for testing procedures
• New onset (<3 months on a stable regime) hormone replacement therapy
• Current use of beta-adrenergic blocking agents
• Major surgery on the abdomen, pelvis, or lower extremities within previous 3 months
• Previous bariatric or other surgery for obesity
• Abnormal blood count/anemia (hemoglobin <12 g/dl in men or 11 g/dl in women; Hct <34%), blood transfusion or blood donation within the last 2 months
• Current smokers (smoking within the past 3 months prior to screening visit, including any/all tobacco products)
• Current drug or alcohol abuse/dependence, or positive urine toxicology screen
• Alcohol consumption >7 drinks per week for women or 14 drinks per week for men or history of binge drinking (≥5 drinks for males or 4 drinks for females in a 2-hour period more than once per month)
• Metal implants (pacemaker, aneurysm clips) based on investigator's judgment at screening
• Not physically capable of performing the exercise required of the study protocols

Where it is running

• AdventHealth Translational Research Institute — Orlando, Florida, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.